The extension, released shortly before the flexibilities were set to expire at the end of 2025, gives regulators more time to ...

The American Telemedicine Association announced that the U.S. Drug Enforcement Administration, or DEA, granted a 1-year ...

DEA extends telemedicine prescribing flexibilities through 2026, allowing remote controlled substance prescriptions without in-person visits.

The extension allows providers to continue remotely prescribing Schedule II–V controlled substances under specific conditions to prevent a disruptive "telemedicine cliff." ...

The Drug Enforcement Administration (DEA) published a yearlong extension of telemedicine prescribing flexibilities for controlled substances Tuesday, just one day before the end of the year, when the ...

The Drug Enforcement Administration (DEA) just released a new regulation temporarily extending the COVID-era flexibilities for prescribing controlled substances via telemedicine. This third extension ...

On January 16, the U.S. Drug Enforcement Administration (DEA) announced three new telemedicine rules that extend prescribing flexibilities for controlled substances, following the expiration of ...

The Drug Enforcement Administration (DEA) has finalized quotas for legal production of controlled substances in 2026—further ...

The U.S. Drug Enforcement Agency is, for a second time, extending clinicians’ ability to prescribe controlled substances using telehealth services, according to a revised rule the agency published.

The Drug Enforcement Agency's (DEA) Office of Diversion Control regulates the purchase, storage and use of controlled substances under Title 21 Code of Federal Regulations Part 1300. The Office of ...